Loading stock data…
Rallybio Corporation (RLYB)
$16.06+0.06 (+0.37%)
Market ClosedLast close Jun 29
Rallybio Corporation, a clinical-stage biotechnology company, engages in the development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Rallybio Corporation in the Healthcare sector is trading at $16.06 with a market capitalization of $93M. The stock is currently near its 52-week high of $17.57, remaining 101.8% above its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the safe zone. The Whystock Score of 80/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $212,000↓ | $222,000↑ | $212,000 | $212,000 | $212,000 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$8.73M↓ | -$6.41M↑ | -$6.92M↑ | -$10.06M↓ | -$9.67M |
| Net Income | -$8.28M↓ | -$5.85M↓ | $16.02M↑ | -$9.70M↓ | -$9.44M |
Peer Comparison
JNJUNHPFE
Fundamentals
Rallybio Corporation, a clinical-stage biotechnology company, engages in the development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is the RLYB116, an inhibito...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$93.21M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-15.55%
Volume
Today's trading volume
31,293
Recent News
VERAXA Biotech Expands R&D Hub in Heidelberg as Programs Advance Towards Clinical Development
By Daniella Parra VERAXA Biotech AG (Nasdaq: VRXA)has expanded its R&D facility in Heidelberg, Germany, increasing laboratory space by more than 60% to support team growth and accelerate its cancer therapy programs toward clinical development, the company said. The expansion strengthens research capabilities while allowing the company to remain in Heidelberg’s leading medical oncology hub […] The post VERAXA Biotech Expands R&D Hub in Heidelberg as Programs Advance Towards Clinical Development a
Prolium Bioscience Sclerosis, Lupus Treatment Studies Advancing
By Karen Roman Prolium Bioscience, Inc. said it dosed its first patient in Phase 1/2 study of PRO-203, a T-cell engager treatment for systemic sclerosis, following the completion of a study in 20 healthy volunteers. The company also completed the last patient and visit in a 26-week study of PRO-203 in treatment-refractory lupus nephritis patients, […] The post Prolium Bioscience Sclerosis, Lupus Treatment Studies Advancing appeared first on ExecEdge.
RLYB Stock Hits 2-Year Highs After Unveiling Merger With Avenzo – How Much Of The New Company Will Rallybio Shareholders Own?
Rallybio announced a merger agreement with Avenzo Therapeutics to create a publicly traded, oncology-focused biotechnology company.
RallyBio tries again for reverse merger, this time with Avenzo
It's the second attempt for the rare disease company, which initially announced plans to merge with Candid Therapeutics before the immune drug developer was bought by UCB.
Rallybio to acquire Candid Therapeutics
The combined cash balance at closing is projected to fund operations through 2030.